Navigation Links
NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Date:9/11/2007

SOPHIA ANTIPOLIS, France, Sept. 11 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has disclosed promising top-line results from its first phase 2 clinical study for TPI-1020, a new chemical entity licensed from NicOx which is a novel respiratory anti- inflammatory. These results showed a good safety and tolerability profile, in addition to certain anti-inflammatory effects, which could be beneficial in TOPIGEN's target indication of Chronic Obstructive Pulmonary Disease (COPD). TOPIGEN plans to initiate a phase 2 study in patients with COPD during the second half of 2007 (see TOPIGEN's press release enclosed).

Damian Marron, Vice-President of Corporate Development at NicOx, declared: "These results indicate that TPI-1020 is safe and well tolerated in patients with respiratory disease and confirm its potential for enhanced clinical efficacy, as previously suggested by preclinical models of COPD. These positive data demonstrate the potential of NicOx' technology in the respiratory area and the quality of our alliance with TOPIGEN, whose expertise in this therapeutic area has been invaluable. NicOx and TOPIGEN are excited by this opportunity to develop an effective treatment for the millions of people suffering from COPD and looks forward to the initiation of a new trial in this indication later this year."

This trial was initiated in May 2006 and was a 21-day, multi-center, double blind trial in asthmatic smokers who were randomized to receive repeated and ascending doses of either inhaled TPI-1020 or budesonide, a conventional corticosteroid which is used in respiratory disorders (see press release of May 23, 2006). The top-line results of this trial revealed a good safety and tolerability profile, in addition to certain anti-inflammatory effects which could be beneficial in the treatment of COPD. TOPIGEN plans to initiate a phase 2 trial for TPI-1020 in COPD during the second half of 2007.

About C
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- According to data released today by the Centers for ... Part D premium is expected to remain stable at ... the Pharmaceutical Care Management Association (PCMA) said. ... bright spot in American health care. By offering an ... cutting edge, cost-saving tools like pharmacy networks and home ...
(Date:7/31/2014)... -- ResMed Inc. (NYSE: RMD ) today announced results ... June 30, 2014.  Revenue for the quarter was $415.2 million, ... 1 percent decrease on a constant currency basis). Net income ... the quarter ended June 30, 2013. Diluted earnings per share ... compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... 31, 2014  Cepheid (NASDAQ: CPHD ) today ... conferences, and invited investors to participate via webcast. ... New York, NY Wednesday, August 13, 2014 at ... Conference, New York, NY Thursday, September ... Accessing Live Webcasts To access the live webcasts for these ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2
... Inc. (NASDAQ: IDIX ), a biopharmaceutical company ... the treatment of human viral diseases, today announced that ... and Lead Director of Idenix,s Board and former President ... as Chairman of the Board. Additionally, Idenix has appointed ...
... Inc. (NASDAQ: AVNR ) today announced that company management ... & Company Healthcare Conference , Location: Boston Marriott, Boston , MA ... a.m. ET , 2012 Roth OC Growth ... Date: Tuesday March 13, 2012 , Presentation time: 4:30 p.m. PT ...
Cached Medicine Technology:Idenix Pharmaceuticals Elects Thomas Hodgson as Chairman of the Board and Appoints Michael Wyzga to Its Board of Directors 2
(Date:8/1/2014)... The European gas chromatography systems report defines and segments ... revenue. The gas chromatography systems market in Europe is valued ... to around $247.6 million by 2018, at a CAGR of ... of the European gas chromatography systems market, to get an ... glimpse of the segmentation of gas chromatography systems market in ...
(Date:8/1/2014)... Agebc.com, a renowned wedding dress manufacturer and retailer, has revealed ... matter of fact, all items in this range are well ... them are offered at promotional prices now, up to 68% ... for clients who want to be beautiful without spending too ... period of time. Ladies who want to get cheap special ...
(Date:8/1/2014)... America (GSA) the nation,s largest interdisciplinary organization ... Sean P. Curran, PhD, of the University of Southern ... New Investigator Award. , This distinguished honor is given ... basic biological research. It was established in 1986 to ... and pioneer in gerontological research at the National Institutes ...
(Date:8/1/2014)... Lifeinsurancenomedicalexam.info has released a new blog post explaining ... high cholesterol levels. , Clients who have a ... medical exam life insurance. These plans offer a convenient ... Since there are no medical examinations involved, clients who ... a few minutes. However, this convenience comes at a ...
(Date:8/1/2014)... Hyden, KY (PRWEB) August 01, 2014 ... the Health Resources and Services Administration’s Advanced Education ... $700,000 and will provide direct support to 280 students ... of the AENT Program is to increase the number ... care providers and/or nursing faculty to address the nurse ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Cheap Prom Dresses At The Renowned Dresses Manufacturer and Retailer Agebc.com 2Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Frontier Nursing University Receives $700,000 in Scholarships for Advanced Practice Nursing and Midwifery Students 2
... Facilities Treated with the Antimicrobial Protection of the ... SportsAide(R) System from SportCoatings(TM), EAST ... are,the next team in the NBA scoring with the ... antimicrobial contamination. SportsAide is part of the Sports ...
... Meeting Expectations today announced,that it has been named ... the industry,s,largest and most influential full-service independent meeting ... market. Compiled by,Penton Media,s Corporate Meetings & Incentives(R) ... corporate meetings and events,industry, the CMI 25 provides ...
... putting patients with heart disease at risk by affecting blood ... the University of Edinburgh and Ume University measured the effects ... men who have previously experienced a heart attack. , ... in the New England Journal of Medicine, found that inhalation ...
... showed effect after brief exposure to diesel exhaust , , ... not to take your daily jog during rush ... exposed, even briefly, to diesel exhaust fumes showed reduced blood ... various cardiovascular problems, including heart attacks and arrhythmias. , The ...
... Sept. 12 Having already made great,strides in ... is,ready to take on America. Terumo Interventional ... Coronary Guidewire to the U.S. market. With its ... this,coronary guidewire boasts efficiency and reliability unlike that ...
... Alliance,for Hispanic Health (the Alliance) is launching a ... (Presion alta...El control,esta en tus manos) with the ... promoting prevention, and helping Hispanic adults bring,their high ... and blood pressure screening events in San Antonio ...
Cached Medicine News:Health News:New Jersey Nets Shoot Down Staph with High-Tech Defense 2Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2Health News:Diesel exhaust may increase risk in patients with heart disease 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 2Health News:Jogging in Traffic Cuts Blood Flow to Heart 3Health News:Proven Terumo Coronary Guidewire Technology Is Now Available in the United States 2Health News:Proven Terumo Coronary Guidewire Technology Is Now Available in the United States 3Health News:Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio 2Health News:Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio 3
... lens available for gonioscopy ... 62 mirror. Tilted anterior ... laser beam astigmatism. Unsurpassed ... on most patients without ...
West lacrimal cannula blunt tip with side port....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
McIntyre lacrimal cannula, dual 0.3 mm side ports, straight....
Medicine Products: